Figure 5From: Immunogenicity in mice and rhesus monkeys vaccinated with recombinant vaccinia virus expressing bivalent E7E6 fusion proteins from human papillomavirus types 16 and 18In vivo tumour protection and treatment experiments using TC-1 tumour cells with recombinant vaccinia virus. Panel A: in vivo tumour protection experiments; C57BL/6 mice (n = 10 per group) were immunised intraperitoneally twice at two weeks interval with 1 × 107 pfu recombinant vaccinia virus rVVJ16/18E7E6 and rVVJ16E6E7, control virus rVVJ1175 or PBS. Two weeks after the last vaccination, mice were challenged subcutaneously in the groin with 1.2 × 104 TC-1 tumour cells. Panel B: the treatment experiments; C57BL/6 mice (n = 10 per group) received 1 × 104 TC-1 cells on day 0 and were vaccinated with in same groups and dose as used in panel A at days 1 and 11. Tumour development was monitored twice a week during a 50-day follow-up. The data in this figure are from one of two similar experiments.Back to article page